Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of Medical Virology|October 4, 2024
Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023Marie-Laure Chaix, Laura Terracol, Marie-Laure Nere, et al.
Plos One|January 16, 2026
A cross-sectional survey to explore healthcare providers' experiences and attitudes toward HIV pre-exposure prophylaxis for women in family planning centers of Greater ParisGeoffroy Liegeon, Joseph A Mason, Eleanor E Friedman, et al.
AIDS Patient Care and Stds|November 27, 2023
Adapting Provider Training and Pre-Exposure Prophylaxis Advertising to Increase Pre-Exposure Prophylaxis Awareness and Uptake Among Black Cisgender WomenSamantha A Devlin, Jessica P Ridgway, Alicia Dawdani, et al.
The Journal of Antimicrobial Chemotherapy|July 19, 2021
Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trialLauriane Goldwirt, Rebecca Bauer, Geoffroy Liegeon, et al.
Sexually Transmitted Diseases|August 15, 2025
Pre-exposure Prophylaxis Prescription Differences at Two Federally Qualified Health CentersEleanor E Friedman, Joseph A Mason, Samantha A Devlin, et al.
The Journal of Antimicrobial Chemotherapy|January 19, 2022
Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virusGeoffroy Liegeon, Nicole Ngo-Giang-Huong, Nicolas Salvadori, et al.
Sexually Transmitted Infections|October 24, 2025
Willingness to participate in a long-acting injectable cabotegravir HIV pre-exposure prophylaxis study among men who have sex with men in the French ANRS-PREVENIR cohortAugust Eubanks, Maxime Hoyer, Abdourahmane Sow, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2022
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR studyGeoffroy Liegeon, Lambert Assoumou, Jade Ghosn, et al.
The Lancet. Infectious Diseases|December 4, 2025
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trialGeorg M N Behrens, Lambert Assoumou, Geoffroy Liegeon, et al.
AIDS (London, England)|May 30, 2024
Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirineEmma Rubenstein, Myriam Diemer, Lauriane Goldwirt, et al.
Pageof 4